A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
← catalyst calendarSponsored by Nurix Therapeutics, Inc. (industry) · NRIX — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
248estimated
Sites
16
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-05-05 | actual | When the study began enrolling |
| Primary completion | May 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | May 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2021-04-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Chronic Lymphocytic Leukemia (CLL)
- Small Lymphocytic Lymphoma (SLL)
- Waldenstrom Macroglobulinemia (WM)
- Mantle Cell Lymphoma (MCL)
- Marginal Zone Lymphoma (MZL)
- Follicular Lymphoma (FL)
- Diffuse Large B-cell Lymphoma (DLBCL)
- Primary Central Nervous System Lymphoma (PCNSL)
Intervention
- Drug: NX-2127
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants with Protocol Specified Dose-Limiting Toxicities
measured Up to 24 months
To establish the MTD and/or recommended Phase 1b dosage(s) of NX-2127
measured Up to 24 months
To evaluate the clinical activity of NX-2127 at the recommended Phase 1b dosage(s) based on overall response rate (ORR) as assessed by the Investigator
measured Up to 4 years
Number of Participants with Adverse Events and Clinical Laboratory Abnormalities
measured Up to 5 years
Publications
- PMID 36375120 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · NRIX's whole pipeline · Catalyst calendar · Every registered study · What changed